Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T Therapy

▴ Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T Therapy
Tessa announced, EMA has granted PRiority MEdicines designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma

Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumours, today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).

PRIME is a program launched by EMA to optimize development plans and speed up evaluation of medicines that demonstrate major therapeutic advantage over existing treatments, or otherwise benefit patients without treatment options. Through this program, EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for accelerated evaluation by the agency.

"We are very pleased that EMA has acknowledged the potential Tessa's CD30 CAR-T therapy holds for patients with Hodgkin Lymphoma" said Jeffrey H. Buchalter, President and CEO of Tessa Therapeutics. "Having received RMAT designation from FDA during 2020, we now hope to work closely with regulatory agencies in both the United States and Europe to expedite clinical development and the registration path for this therapy."

The PRIME designation was granted by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center. These studies showed complete disappearance of tumour in ~60% of patients at the highest dose level with none of the serious toxicities that can be associated with several other CAR-T therapies. These results were published in Journal of Clinical Oncology (Ramos et al., 2020). Based on these data, Tessa plans to commence a multi-center pivotal study in the United States during 2021.

Europe accounts for approximately a quarter of the world's Hodgkin Lymphoma incidence. Tessa's pivotal trial will be recruiting patients from more than 20 cancer centers across the US and Europe including sites in Italy, Spain and Sweden. "CD30 CAR-Ts demonstrated excellent safety and efficacy data in heavily pre-treated R/R cHL patients. We look forward to collaborating with Tessa to further validate these impressive results in the pivotal trial." said Dr Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Italy.

Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics said "CD30 CAR-T therapy, with its promising efficacy and very limited toxicity, can meaningfully address current gaps that exist in the treatment of R/R cHL. We also are exploring the potential of this therapy in CD30 positive subtypes of Non-Hodgkin Lymphoma (NHL)." Tessa's Phase 1 clinical study for patients with relapsed / refractory CD30 positive NHL is open for enrollment in the United States.

Tags : #TessaTherapeutics #LatestNewsonTessaTherapeutics #LatestPharmaNews19thJan #LatestNewsonCancerTreatment #EuropeanMedicinesAgency #USFDA

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Why are key populations on the blindspot in the global HIV response?July 20, 2024
Exploring the Link Between Tinnitus and Body Composition: What Recent Research RevealsJuly 20, 2024
Surge in Brain Infections in India During Monsoon: A Growing ConcernJuly 20, 2024
We have more infection-prevention options now but are they actual choices for the people?July 19, 2024
New humidity-driven membrane to remove carbon dioxide from the airJuly 19, 2024
Introducing the World's First Consent-Based Data-Sharing Framework Built on Open Standards: The Affinidi Iota Framework July 19, 2024
The Power of Green Spaces: Evidence That Parks May Delay Cognitive DeclineJuly 19, 2024
Strengthening Healthcare in India: The Push for Better Coverage with Ayushman BharatJuly 19, 2024
SARV Events & Celebrations Shines at "Edu-Bizz Leadership Summit & Awards 24July 18, 2024
UAE launches global initiative to build 10 hospitals to address critical healthcare gaps as part of Zayed Humanitarian Legacy InitiativeJuly 18, 2024
Geetanjali Homestate Expands Global Presence with the Launch of Geetanjali GlobalJuly 18, 2024
Changes projected in marine fish communities due to climate changeJuly 18, 2024
Understanding the Chandipura Virus Outbreak in Gujarat: A Critical OverviewJuly 18, 2024
Landmark Study Links Severe Endometriosis to Increased Risk of Ovarian CancerJuly 18, 2024
Equipping Healthcare Professionals for Global Opportunities: GIMS Partners with NSDCJuly 18, 2024
Hormone Modulating Therapy for Breast Cancer and Its Link to Lower Alzheimer’s RiskJuly 18, 2024
Multipl Secures $1.5 Million in Additional Funds, Led by Blume Ventures and MIXI Global Investments, JapanJuly 17, 2024
FedEx to empower youth with digital skilling programJuly 17, 2024
Putting people first means following Gandhi's TalismanJuly 17, 2024
American Oncology Institute (AOI) Launches #BreaktheHabit Campaign to Raise Awareness on Head & Neck cancerJuly 17, 2024